![Prediction of dose distribution from luminescence image of water using a deep convolutional neural network for particle therapy - Yabe - 2020 - Medical Physics - Wiley Online Library Prediction of dose distribution from luminescence image of water using a deep convolutional neural network for particle therapy - Yabe - 2020 - Medical Physics - Wiley Online Library](https://aapm.onlinelibrary.wiley.com/cms/asset/62bb3a9d-04b2-4747-a819-4aba208108dd/mp14372-fig-0001-m.jpg)
Prediction of dose distribution from luminescence image of water using a deep convolutional neural network for particle therapy - Yabe - 2020 - Medical Physics - Wiley Online Library
![Prediction of dose distribution from luminescence image of water using a deep convolutional neural network for particle therapy - Yabe - 2020 - Medical Physics - Wiley Online Library Prediction of dose distribution from luminescence image of water using a deep convolutional neural network for particle therapy - Yabe - 2020 - Medical Physics - Wiley Online Library](https://aapm.onlinelibrary.wiley.com/cms/asset/b1001e71-35c3-463c-9463-77a569edbb97/mp14372-fig-0008-m.jpg)
Prediction of dose distribution from luminescence image of water using a deep convolutional neural network for particle therapy - Yabe - 2020 - Medical Physics - Wiley Online Library
![Landscape and representative microhabitat dose rates at Kamitashiro,... | Download Scientific Diagram Landscape and representative microhabitat dose rates at Kamitashiro,... | Download Scientific Diagram](https://www.researchgate.net/profile/Ken-Ishida/publication/292346730/figure/fig2/AS:324920342007814@1454478454232/Landscape-and-representative-microhabitat-dose-rates-at-Kamitashiro-Yamakiya-Kawamata.png)
Landscape and representative microhabitat dose rates at Kamitashiro,... | Download Scientific Diagram
![Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. - Journal Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. - Journal](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/cfd7c16d-2bb8-419e-9640-3161472c49da/gr1_lrg.jpg)
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. - Journal
![Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded,](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/994abe4d-01fd-4a3c-9a37-fca8ec3521f2/gr1.gif)
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded,
![Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/f3be98d8-d68c-4273-a286-fc9e5079f0d6/gr1.jpg)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet
![Technetium-99m-HMPAO, Technetium-99m-ECD and Iodine-123-IMP Cerebral Blood Flow Measurements with Pharmacological Interventions in Primates | Journal of Nuclear Medicine Technetium-99m-HMPAO, Technetium-99m-ECD and Iodine-123-IMP Cerebral Blood Flow Measurements with Pharmacological Interventions in Primates | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/38/12/1897.extract.jpg)
Technetium-99m-HMPAO, Technetium-99m-ECD and Iodine-123-IMP Cerebral Blood Flow Measurements with Pharmacological Interventions in Primates | Journal of Nuclear Medicine
![Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/db5c63dc-ee49-4b78-b05c-e93ffa8229af/gr1_lrg.jpg)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet
The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man.
Deep Learning–based Reconstruction for Lower-Dose Pediatric CT: Technical Principles, Image Characteristics, and Clinical Impl
![G Live on Twitter: "Vaccinations Update: 18-39 yr olds can walk-in & get the Pfizer vaccine @GLiveGuildford until 7pm today. Pfizer also available for 18-39 yr olds on Fri 8am-7pm & Sat G Live on Twitter: "Vaccinations Update: 18-39 yr olds can walk-in & get the Pfizer vaccine @GLiveGuildford until 7pm today. Pfizer also available for 18-39 yr olds on Fri 8am-7pm & Sat](https://pbs.twimg.com/media/E5neQ-MWYAMA0lX.jpg)
G Live on Twitter: "Vaccinations Update: 18-39 yr olds can walk-in & get the Pfizer vaccine @GLiveGuildford until 7pm today. Pfizer also available for 18-39 yr olds on Fri 8am-7pm & Sat
![Eastern Railway on Twitter: "Rail hospital scales new height in vaccination https://t.co/ubdGuCwV2l" / Twitter Eastern Railway on Twitter: "Rail hospital scales new height in vaccination https://t.co/ubdGuCwV2l" / Twitter](https://pbs.twimg.com/media/FJiMr2yaMAQ-s_E.jpg)
Eastern Railway on Twitter: "Rail hospital scales new height in vaccination https://t.co/ubdGuCwV2l" / Twitter
![Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) - The Lancet Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/410a9d2d-7aa0-4f9f-88d4-fa3968c5b2cc/gr5.jpg)
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) - The Lancet
![Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial - Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial -](https://ars.els-cdn.com/content/image/1-s2.0-S2352301821001570-gr2.jpg)
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial -
![Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-020-01179-4/MediaObjects/41591_2020_1179_Fig2_HTML.png)
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine
![T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | Nature Medicine T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-01194-5/MediaObjects/41591_2020_1194_Fig1_HTML.png)
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | Nature Medicine
Dose-related effect of trisodium nitrilotriacetate monohydrate on renal tumorigenesis initiated with N-ethyl-N-hydroxyethyl- nit
Apoptosis-Related Gene and Protein Expression in Human Lymphoma Xenografts (Raji) After Low Dose Rate Radiation Using 67Cu-2IT-B
![Highly pathogenic avian influenza virus H5N1 controls type I IFN induction in chicken macrophage HD-11 cells: a polygenic trait that involves NS1 and the polymerase complex | Virology Journal | Full Text Highly pathogenic avian influenza virus H5N1 controls type I IFN induction in chicken macrophage HD-11 cells: a polygenic trait that involves NS1 and the polymerase complex | Virology Journal | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1743-422X-9-7/MediaObjects/12985_2011_Article_1674_Fig1_HTML.jpg)